Sugi Predict

Sugi Predict / Targets / WEE2

WEE2

Wee1-like protein kinase 2 · P0C1S8 · WEE2 on Sugi Atlas →

6,430 patent compounds predicted against WEE2, 5,872 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Bosutinib Bosutinib (SCHEMBL158390) 1.00 2/20
Bosutinib Bosutinib (SCHEMBL2887945) 1.00 2/20
SCHEMBL934766 SCHEMBL934766 0.82 2/20
SCHEMBL933446 SCHEMBL933446 0.81 2/20
SCHEMBL2133125 SCHEMBL2133125 0.80 2/20
SCHEMBL2205691 SCHEMBL2205691 0.78 2/20
SCHEMBL2205695 SCHEMBL2205695 0.78 2/20
Hki-357 Hki-357 (SCHEMBL2203413) 0.78 2/20
Hki-357 Hki-357 (SCHEMBL2203420) 0.78 2/20
SCHEMBL2203827 SCHEMBL2203827 0.74 2/20
SCHEMBL2203831 SCHEMBL2203831 0.74 2/20
SCHEMBL2131997 SCHEMBL2131997 0.73 2/20
SCHEMBL2204131 SCHEMBL2204131 0.73 2/20
SCHEMBL2204137 SCHEMBL2204137 0.73 2/20
SCHEMBL2129849 SCHEMBL2129849 0.71 2/20
SCHEMBL2152700 SCHEMBL2152700 0.56 2/20
SCHEMBL729258 SCHEMBL729258 0.43 2/20
SCHEMBL728879 SCHEMBL728879 0.41 2/20
SCHEMBL722798 SCHEMBL722798 0.40 2/20
SCHEMBL729216 SCHEMBL729216 0.40 2/20

Clinical trials — most relevant to WEE2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression PHASE3RECRUITING
Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer PHASE2COMPLETED
CISPLATIN + AZD-1775 In Breast Cancer PHASE2COMPLETED
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma PHASE2ACTIVE_NOT_RECRUITING
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification PHASE2COMPLETED
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. PHASE2ACTIVE_NOT_RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment PHASE2NOT_YET_RECRUITING
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency PHASE2COMPLETED
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies PHASE1COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia PHASE1WITHDRAWN
Study of SGR-3515 In Participants With Advanced Solid Tumors. PHASE1RECRUITING
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors PHASE1RECRUITING
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer EARLY_PHASE1WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma nanCOMPLETED
Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer nanACTIVE_NOT_RECRUITING
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome nanACTIVE_NOT_RECRUITING
Biomarkers in Samples From Patients With Endometrial Cancer nanWITHDRAWN
Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy nanCOMPLETED
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions nanCOMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a WEE2 binder may also engage these)

ProteinNameSimilarity
A4QNA8 — 0.997 A4QNA8 →
E1BTE1 — 0.996 E1BTE1 →
A4PES0 — 0.996 A4PES0 →
Q6DFE0 — 0.996 Q6DFE0 →
E2RSS3 — 0.995 E2RSS3 →
D2HHP1 — 0.995 D2HHP1 →
Q66JT0 — 0.995 Q66JT0 →
O57473 — 0.994 O57473 →
Q1LX51 — 0.994 Q1LX51 →
P47817 — 0.992 P47817 →
Q6Z829 — 0.987 Q6Z829 →
Q9Z2R9 — 0.986 Q9Z2R9 →
Q8L4H0 — 0.984 Q8L4H0 →
D4A7V9 — 0.984 D4A7V9 →
EIF2AK4 eIF-2-alpha kinase GCN2 0.983 landscape →
P54350 — 0.983 P54350 →
Q4R8E0 — 0.983 Q4R8E0 →
P33279 — 0.983 P33279 →
Q9QZ05 — 0.982 Q9QZ05 →
Q8RXT4 — 0.982 Q8RXT4 →
Q68UT7 — 0.982 Q68UT7 →
P35761 — 0.982 P35761 →
Q8NG08 — 0.982 Q8NG08 →
NEK11 Serine/threonine-protein kinase Nek11 0.982 landscape →
Q8GT06 — 0.982 Q8GT06 →
PARG Poly(ADP-ribose) glycohydrolase 0.981 landscape →
Q8AYG3 — 0.981 Q8AYG3 →
Q5TKR9 — 0.981 Q5TKR9 →
Q8BMI4 — 0.980 Q8BMI4 →
Q1LYM3 — 0.980 Q1LYM3 →